NanoViricides
NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics based on a proprietary host-mimetic polymeric micelle platform, with lead candidate NV-387 in Phase II trials for mpox and ebola and FDA Orphan Drug Designation for measles.
- Company typePublic
- Founded2005
- HeadquartersWest Haven, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NanoViricides does
NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company founded in 2005 and listed on NYSE American under ticker NNVC. The company is developing a pipeline of antiviral therapeutics built on a proprietary host-mimetic nanomedicine platform licensed from TheraCour Pharma. The core technology uses polymeric micelles that mimic heparan sulfate proteoglycan (HSPG) receptors on host cell surfaces; because 90–95% of known human pathogenic viruses require HSPG for cell entry, the platform claims viruses cannot escape its mechanism through mutation. The lead drug candidate, NV-387, is formulated as an oral gummy and has demonstrated broad-spectrum activity in animal models against RSV, COVID-19, influenza, mpox, smallpox, measles, and ebola. NV-387 received FDA Orphan Drug Designation for measles in April 2026 and is in Phase II trials for mpox (Clade I) and Bundibugyo ebola in the Democratic Republic of Congo, supported by CRO Om Sai Clinical Research.
The company operates with 1–10 employees from a headquarters and cGMP-capable manufacturing facility in Shelton, Connecticut. Additional pipeline assets include NV-HHV-1 for shingles, NV-CoV-2 and NV-CoV-2-R (the latter encapsulating remdesivir) for COVID-19, HerpeCide for herpes viruses, FluCide for influenza, and HIVCide for HIV. Business model is pre-revenue: NanoViricides funds operations through periodic registered direct equity offerings (e.g., $6M in November 2025 and $2M in May 2026 with D. Boral Capital as placement agent) plus a $3M unused credit line from founder Dr. Anil R. Diwan. Anticipated revenue streams post-approval include US Strategic National Stockpile contracts for pandemic preparedness (modeled on TPOXX/TEMBEXA deals worth hundreds of millions of dollars), a potential Priority Review Voucher (~$150–200M) tied to a measles Rare Pediatric Disease Designation, and orphan drug market exclusivity. The company has disclosed that cash on hand as of March 31, 2026 is insufficient to fund operations beyond mid-February 2026 without additional financing.
NanoViricides firmographics
Firmographics- Name
- NanoViricides
- Legal name
- NanoViricides, Inc.
- Website
- https://nanoviricides.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics based on a proprietary host-mimetic polymeric micelle platform, with lead candidate NV-387 in Phase II trials for mpox and ebola and FDA Orphan Drug Designation for measles.
- Ownership category
- akta.pro rank
NanoViricides industry classification
Industry- Product category
- Antiviral Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Nanobodies & Alternative Antibody Scaffolds (HLAAAAAG)
Keywords
Where NanoViricides is headquartered
LocationHeadquarters
- HQ city
- West Haven
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NanoViricides business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations
Revenue model
- Pharmaceutical Drug Sales: Revenue from commercial sales of approved antiviral drugs following successful clinical development and regulatory approval. Target markets include RSV, influenza, COVID-19, mpox, smallpox, and measles treatments with estimated market sizes exceeding $25 billion.
- Government SNS Stockpiling Contracts: US Government Strategic National Stockpile contracts for pandemic preparedness bioterrorism agents. Existing smallpox drugs TPOXX and TEMBEXA represent several hundreds of millions of dollars in potential opportunity for NV-387 if approved.
- Priority Review Voucher (PRV): Upon FDA approval of NV-387 for Rare Pediatric Disease (measles), company may receive transferable PRV worth estimated $150-200 million that can be sold to other pharmaceutical companies.
- Orphan Drug Market Exclusivity: FDA Orphan Drug Designation provides 7 years of market exclusivity upon approval, tax credits for clinical trials, and exemption from certain user fees. Received ODD for measles treatment.
- Non-Dilutive Grant Funding: Pursuing US government grants for development of pandemic preparedness countermeasures, particularly for measles treatment development in the USA.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
NanoViricides product offering
Product offeringCore offering
NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics using its proprietary nanoviricide platform technology. The platform uses polymeric micelle-based nanomedicines that mimic host cell receptors (heparan sulfate proteoglycans) to bind, engulf, and destroy viruses. Its lead drug candidate NV-387, formulated as oral gummies, is in Phase II clinical trials targeting mpox, ebola, measles, RSV, COVID-19, and influenza.
Product overview
NanoViricides is a clinical-stage nano-biopharmaceutical company developing antiviral drugs using its proprietary nanoviricide® platform technology. The lead product is NV-387, a broad-spectrum antiviral drug in Phase II clinical trials for MPox and Ebola treatment, with Orphan Drug Designation for Measles. The company also has NV-HHV-1 for Shingles, NV-CoV-2 and NV-CoV-2-R for COVID-19, and earlier-stage candidates for HIV, Influenza (FluCide), Dengue, Rabies, and Ebola/Marburg. The platform technology mimics host cell receptors that viruses bind to, creating drugs that viruses cannot escape through mutation.
Differentiator
Problem solved
Functional benefit
Brands
- NV-387: Broad-spectrum antiviral drug candidate targeting RSV, COVID-19, Influenza, MPox, Smallpox, and Measles
- NV-HHV-1
- NV-CoV-2
- NV-CoV-2-R
- HerpeCide
- FluCide
Products and services
- NV-387 Oral Gummies Broad-spectrum antiviral drug candidate that mimics host cell features (heparan sulfate proteoglycan) to bind and destroy viruses. Effective against RSV, COVID-19, Influenza, MPox, Smallpox, Measles, and Ebola. Administered as oral gummies. In Phase II clinical trials.
- NV-HHV-1
- NV-CoV-2 Nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. Based on the NV-387 platform technology.
- NV-CoV-2-R COVID-19 drug candidate composed of NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes this may be an approvable drug if safety is comparable to remdesivir.
- HerpeCide Program (NV-HHV-101) Broad-spectrum drug program targeting herpes viruses including HSV-1 (cold sores), HSV-2 (genital herpes), and herpes keratitis (eye drops). Topical treatment advancing toward IND filing.
- FluCide Program Drug candidates against all influenzas including H1N1 swine flu and H5N1 bird flu at different preclinical stages.
- HIVCide Pan-HIV drug candidate based on host-cell-mimetic nanoviricide technology, potentially for functional cure.
Quantifiable outcome
- 170% survival improvement over untreated animals for NV-387 IV vs 40% for remdesivir in lethal COVID-19 animal model
- +4 more outcomes
Companies that use NanoViricides
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
NanoViricides technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NanoViricides partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Only Orphans Cote, LLCcoreRegulatory consulting firm founded by former FDA Office of Orphan Products Development Director Dr. Timothy Cote engaged to develop orphan drug strategy for NV-387 targeting Mpox, Smallpox, and Measles. Master Services Agreement signed December 1, 2025 for preparing and prosecuting orphan drug designation applications with US FDA.
- TheraCour Pharma, Inc.coreLicensing partner holding intellectual property for nanoviricide technology. NanoViricides has Memorandum of Understanding with TheraCour for development of drugs based on these technologies for all antiviral infections. The company holds broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour.
- Om Sai Clinical Research Private LimitedcoreCRO retained for Phase II clinical trials in DRC. Instrumental in successful submission of proposal to Pillar Committee for Phase II Ebola clinical trial. Conducting site preparations and staff training for mpox trial in DRC with associates in country.
- AllExcel, Inc.coreTechnology licensor for TheraCour nanomedicine platform technology. TheraCour licenses the TheraCour technology from AllExcel. NanoViricides holds exclusive perpetual license to this technology for specific antiviral applications.
- Gilead SciencesminorRemdesivir developer referenced in context of NV-CoV-2-R drug candidate that encapsulates remdesivir within nanoviricide polymeric micelles. Company states that since remdesivir is already FDA approved, their drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Developed independently by NanoViricides.
- BASi (Bioanalytical Systems, Inc.)minorContract research organization engaged for IND-enabling Safety/Toxicology studies for shingles drug candidate NV-HHV-101 beginning December 2018. Studies typically last six to nine months.
- Academic and Research CollaboratorsminorMultiple collaborations at leading academic, private, and federal laboratories performing independent nanoviricide testing against various viral targets. Core IP studies performed internally while biological effectiveness and safety studies performed by external collaborators.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
NanoViricides competitors and assessment
Company assessmentDirect peers
- SIGA Technologies: SIGA Technologies develops TPOXX (tecovirimat), the leading FDA-approved smallpox antiviral that NanoViricides explicitly benchmarks against for NV-387 in orthopoxvirus indications. Both companies target US Strategic National Stockpile contracts for pandemic preparedness and bioterrorism response.
- Emergent BioSolutions: Emergent BioSolutions manufactures TEMBEXA (brincidofovir), another US-government stockpiled smallpox antiviral referenced by NanoViricides as a comparable commercial opportunity. Both companies compete in the pandemic preparedness and biodefense procurement space.
- Vir Biotechnology: Vir Biotechnology develops monoclonal antibody-based antivirals for influenza, COVID-19, RSV, and hepatitis B, directly competing in the same broad-spectrum antiviral market NanoViricides targets. Vir's antibody platform represents an alternative modality to NanoViricides' host-mimetic nanomedicine approach.
- Cocrystal Pharma: Cocrystal Pharma is a clinical-stage antiviral biotech developing oral broad-spectrum antiviral candidates for influenza, COVID-19, and norovirus. Like NanoViricides, it is a small public company pursuing innovative antiviral mechanisms without approved products.
- Atea Pharmaceuticals: Atea Pharmaceuticals develops oral direct-acting antivirals, most notably for hepatitis C and COVID-19 (in partnership with Roche). The company represents a comparable small-cap clinical-stage antiviral biotech pursuing oral formulations to compete in similar indications.
- BioCryst Pharmaceuticals: BioCryst Pharmaceuticals markets oral antivirals including Rapivab (peramivir) for influenza and is developing BCX-7353 for hereditary angioedema. As a commercial-stage antiviral company, BioCryst represents the trajectory NanoViricides aspires to in respiratory viral infections.
- Chimerix: Chimerix develops antivirals including TEMBEXA (acquired from Emergent) and is developing dordaviprone for recurrent gliomas. The company's focus on orthopoxvirus treatments and smallpox preparedness directly overlaps with NanoViricides' mpox/smallpox program.
Broad incumbents
- Gilead Sciences: Gilead developed remdesivir, the COVID-19 antiviral that NanoViricides' NV-CoV-2-R candidate aims to improve upon by encapsulating remdesivir in polymeric micelles. Gilead's established antiviral franchise, global commercial infrastructure, and pipeline of nucleotide analog drugs make it both a benchmark and a competitive threat.
Emerging players
- Arbutus Biopharma: Arbutus Biopharma develops antiviral therapies targeting hepatitis B and coronaviruses using novel mechanisms. As a clinical-stage antiviral biotech, it parallels NanoViricides' risk profile and focus on chronic and emerging viral infections.
- Inovio Pharmaceuticals: Inovio Pharmaceuticals develops DNA-based vaccines and antivirals targeting HPV, COVID-19, and other infectious diseases. As a small clinical-stage biotech focused on viral diseases, it shares NanoViricides' profile of pre-revenue operation dependent on capital markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NanoViricides social profiles
Digital presenceNanoViricides financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoViricides leadership team
Management profileNumber of profiles
Profiles7 records
NanoViricides funding detail
Funding detailFunding overview
Funding rounds10 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoViricides M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoViricides
What does NanoViricides do?
NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral therapeutics using its proprietary nanoviricide platform technology. The platform uses polymeric micelle-based nanomedicines that mimic host cell receptors (heparan sulfate proteoglycans) to bind, engulf, and destroy viruses. Its lead drug candidate NV-387, formulated as oral gummies, is in Phase II clinical trials targeting mpox, ebola, measles, RSV, COVID-19, and influenza.
Is NanoViricides a public or private company?
NanoViricides is a public company. It is classified as public and is currently operating.
When was NanoViricides founded?
NanoViricides was founded in 2005. It employs 1 to 10 people.
Where is NanoViricides based?
NanoViricides is headquartered in West Haven, United States, in the North America region.
How does NanoViricides make money?
Five revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are government SNS Stockpiling Contracts, priority Review Voucher (PRV), orphan Drug Market Exclusivity and non-Dilutive Grant Funding.
Who are NanoViricides's main competitors?
Direct peers on record are SIGA Technologies, Emergent BioSolutions, Vir Biotechnology, Cocrystal Pharma, Atea Pharmaceuticals, BioCryst Pharmaceuticals and Chimerix. Gilead Sciences is listed as a broad incumbent. Emerging players are Arbutus Biopharma and Inovio Pharmaceuticals.
Does NanoViricides have an API?
No public API is recorded for NanoViricides.
What industry is NanoViricides in?
NanoViricides's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAAAG, Nanobodies & Alternative Antibody Scaffolds. Its NAICS code is 325414 and its SIC code is 2834.